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1. Leptin and its receptor
Maintenance or gain of bone mass is associated with hor-
mone and/or heavy mechanical load, either due to obesity or
physical activity [1]. Amongst the many hormones that might
account for the link between energy and bone metabolism is
leptin. In this respect, much attention has focused on the
e¡ects of leptin as a central satiety agent, although in vitro
studies provide evidence for direct e¡ects on speci¢c tissues
and metabolic pathways. The debate related to central and/or
peripheral regulation of bone metabolism by leptin has been
ongoing during the last 2 years. The article by Lee and col-
leagues [2] in this issue further addresses this topic, and pro-
vides evidence that functional leptin receptors are expressed in
rat osteoblasts. These results point towards a more direct role
of leptin in bone growth.
Since its discovery in 1994 [3], leptin has been acknowl-
edged as an adipocyte-derived signaling molecule, which
may limit food intake and increase energy expenditure via
speci¢c receptors located in the central nervous system. How-
ever, the picture is becoming more complicated, and leptin is
now looked upon as a multi-potent cytokine with both indi-
rect central and direct peripheral e¡ects in di¡erent organs,
tissues and cells. Circulating leptin in adult individuals is
mainly secreted from adipose tissue [3,4], although leptin
polypeptide and mRNA are detected in other tissues like
muscle [5], gastric epithelium [6], bone [7], and in breast epi-
thelial cells [8]. Leptin expression has also been found in ar-
terial wall cells [9] and in normal pituitary and di¡erent types
of pituitary adenomas [10]. In pregnant women, leptin is syn-
thesized and secreted from placental trophoblasts into the
maternal and fetal circulation [11].
Leptin binds to receptors in the hypothalamus [4] which
leads to reduced appetite and increased energy expenditure.
The leptin receptor (OB-R) exhibits considerable homology
with the interleukin-6 (IL-6) receptor and belongs to the cy-
tokine class I receptor family [12]. At least six forms of the
leptin receptor have been found, of which the long signal-
transducing form, OB-RL, presumably mediates most of lep-
tin’s signaling events. It is also the isoform most abundantly
expressed in the hypothalamus [12]. However, the leptin re-
ceptor is expressed in various areas of the central nervous
system, and in many other organs and cell types [13].
The cytokine receptor superfamily is a rapidly growing fam-
ily of receptors. An early and most likely pivotal event for all
subspecies is the activation of one or more members of the
Janus (or JAK) family of tyrosine kinases. The activated JAK
kinases, which form a complex with the cytokine receptor
subunits, induce autophosphorylation as well as phosphoryla-
tion of the receptor. These phosphorylated tyrosines form
binding sites for various signaling molecules that are them-
selves thought to be phosphorylated by JAK kinases, includ-
ing signal transducers and activators of transcription (STATs)
[14], which regulate transcription by adapter proteins like
SH2-containing protein tyrosine phosphatase [15] that recruit
Grb2 complexes thereby initiating the mitogen-activated pro-
tein kinase (MAPK) pathway, and insulin receptor substrate
(IRS) proteins that, through phosphate inositol pathway, are
thought to regulate metabolic events in the cell [16].
2. Central e¡ect
It has been demonstrated in mutant leptin (ob/ob) and lep-
tin receptor (db/db) mouse models that bone formation, like
other homeostatic functions, is systemic regulated. Ducy et al.
[17] found that intracerebroventricular injections of leptin in
obese ob/ob mice decrease bone density. They were not able to
demonstrate leptin receptor expression in osteoblasts from ob/
ob mice, and claimed that leptin does not act directly on bone
cells. Rather, leptin acts through a central pathway following
binding to its receptor(s) in hypothalamic nuclei. The signal
downstream of the hypothalamus to the bone is hitherto un-
known. Bone tissue serves as a target of the nerve system.
From birth on, the growth of nerves parallels the mineraliza-
tion process, and sympathetic nerve ¢bers comprising neuro-
peptide Y (NPY) have been observed in bone [18]. NPY is
known to be a potent stimulator of energy intake under OB-
Rb control [19]. However, NPY causes bone loss, not growth,
when infused intracerebrally [16], indicating that leptin may in
fact use two di¡erent pathways regulating body weight and
bone mass. NPY signaling, through binding to the Y2 recep-
tor, restrains bone growth, as evidenced by the observation
that Y23=3 mice display more and larger femoral trabeculae
than normal mice. However, such animals exhibit a normal
number of osteoblasts which are metabolically more produc-
tive than osteoblasts from normal littermates [20]. Interest-
ingly, the high bone mass found in ob/ob mice was also proven
to be a result of a normal number of osteoblasts making twice
as much bone matrix as the osteoblasts produced in normal
animals [17,21^25].
Endocrine mechanisms are involved in reproduction, as well
as in control of body mass. In this context, leptin might also
regulate bone growth through indirect control of ovarian cy-
cling and estrogen production by promoting release of the
hypothalamic gonadotropin-releasing hormone. Leptin may
further prevent ovariectomy-induced bone loss in rats by sup-
pressing the production of RANK (receptor activator of nu-
clear factor UB) ligand by osteoblastic stromal cells [26].
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3. Direct e¡ect
The fact that bone is resorbed by osteoclasts and subse-
quently replaced by the osteoblasts at multiple skeletal loca-
tions indicates, within a remodeling cycle, direct link between
osteoblasts and osteoclast activity [27]. This paracrine and/or
autocrine regulation of bone turnover may be evoked by os-
teoblast-derived factors like transforming growth factor
(TGF), insulin growth factor (IGF)-I and -II, tumor necrosis
factor (TNF) and interleukins [28].
Recently, leptin was demonstrated to induce di¡erentiation
of marrow stromal cells into osteoblasts, and not to adipo-
cytes [29]. Leptin receptor mRNA [7] and protein [30] expres-
sion has been demonstrated in human osteoblasts, strongly
indicating a direct e¡ect of leptin on bone metabolism. The
article by Lee and colleagues in this issue of the journal clearly
shows that osteoblasts express a functional leptin receptor
capable of conducting an active signal through the Jak/Stat
pathway, a convincing evidence for a direct action of leptin in
these bone cells.
Leptin has been found to elicit important osteoblastic func-
tioning, by inducing mineralized nodules in primary osteo-
blasts and osteosarcoma cells [7,17,22^25]. Leptin has also
been demonstrated to have direct e¡ects on proliferation, dif-
ferentiation, mineralization, and to induce prolonged life span
of human primary osteoblasts by inhibiting apoptosis [31].
The generation of cultured osteoclasts di¡erentiated from pe-
ripheral blood mononuclear cells (PBMCs) and murine spleen
cells is inhibited by leptin [32], indicating that leptin acts lo-
cally to increase bone mass and may contribute to the well-
known linkage of bone resorption and formation.
Maor et al. [33] found that chondrocytes in the growth
centers contain speci¢c binding sites for leptin. Leptin stimu-
lated the width of the chondroprogenitor zone at low concen-
trations, whereas higher concentrations had an inhibitory ef-
fect. They also found that leptin induced both proliferation
and di¡erentiation activities in the mandibular chondyle. Fi-
nally, it was demonstrated that leptin increases the abundance
of the IGF-I receptor and IGF-I receptor mRNA within the
chondrocytes and the progenitor cell population [33]. These
results indicate that leptin acts as a skeletal growth factor with
a direct peripheral e¡ect on skeletal growth centers.
4. Central or peripheral action of leptin in bone growth ^ or
both?
Steppan et al. [30] demonstrated shorter femurs in ob/ob
mice, and that intraperitoneal injections of leptin increased
bone area. Does the locus of leptin injection play a role in
its e¡ects on bone metabolism?
We have presented data showing that leptin is expressed in
mature primary cultures of human osteoblasts and secreted to
the surrounding media [7]. However, we know nothing about
the local leptin concentration within the bone marrow, and
little of the complex interactions between leptin and other
factors from stromal cells, chondrocytes, adipocytes, osteo-
clasts, mononuclear cells and osteoblasts at di¡erent stages
of di¡erentiation in the local bone environment.
Present information on leptin indicates that leptin is in-
volved in at least two di¡erent bone-controlling mechanisms,
a direct stimulatory e¡ect on bone growth, and/or an indirect
suppressive e¡ect on bone through the hypothalamus. The
regulation of bone growth is complex, and leptin adds more
complexity to this picture. The local environment may provide
bone cells with signals favoring constant growth, whereas the
central negative signal determines the density and length regu-
lated by energy metabolism and leptin. Central administration
of recombinant leptin in obese ob/ob mice [17] and normal
mice causes a decrease in bone mass, whereas peripheral ad-
ministration [30] and in vitro studies in cultured cells [31^33]
indicate an increase in bone growth.
*Corresponding author. Fax: (47)-2285-1341.
E-mail address: j.e.reseland@basalmed.uio.no (J.E. Reseland).
aInstitute for Nutrition Research, University of Oslo, P.O. Box 1046
Blindern, N-0316 Oslo, Norway
bInstitute of Medical Biochemistry, University of Oslo, N-0316 Oslo,
Norway
References
[1] Cormier, C. (1991) Curr. Opin. Rheumatol. 3, 457^462.
[2] Lee, Y.-J., Park, J.-H., Ju, S.-K., You, K.-H., Ko, J.S. and Kim,
H.-M. (2002) FEBS Lett., this issue.
[3] Zhang, Y., Proenca, R., Ma¡ei, M., Barone, M., Leopold, L. and
Friedman, J.M. (1994) Nature 372, 425^432.
[4] Stephens, T.W., Basinski, M., Bristow, P.K., Bue-Valleskey,
J.M., Burgett, S.G., Craft, L., Hale, J., Ho¡mann, J., Hsiung,
H.M., Kriauciunas, A., MacKellar, W., Rosteck Jr., P.R.,
Schoner, B., Smith, D., Tinsley, F.C., Zhang, X.-Y. and Helman,
M. (1995) Nature 377, 530^532.
[5] Wang, J.L., Liu, R., Hawkins, M., Barzilai, N. and Rossetti, L.
(1998) Nature 393, 684^688.
[6] Bado, A., Levasseur, S., Attoub, S., Kermorgant, S., Laigneau,
J.P., Bortoluzzi, M.N., Moizo, L., Lehy, T., Guerre-Millo, M.,
Le Marchand-Brustel, Y. and Lewin, M.J. (1998) Nature 394,
790^793.
[7] Reseland, J.E., Syversen, U., Bakke, I., Qvigstad, G., Eide, L.G.,
Hjertner, O., Gordeladze, J.O. and Drevon, C.A. (2001) J. Bone
Miner. Res. 16, 1426^1433.
[8] Smith-Kirwin, S.M., O’Connor, D.M., De Johnston, J., Lancey,
E.D., Hassink, S.G. and Funanage, V.L. (1998) J. Clin. Endo-
crinol. Metab. 83, 1810^1813.
[9] Parhami, F., Tintut, Y., Patel, J.K., Mody, N., Hemmat, A. and
Demer, L.L. (2001) Z. Kardiol. 90 (Suppl. 3), 27^30.
[10] Korbonits, M., Chitnis, M.M., Gueorguiev, M., Jordan, S., Nor-
man, D., Kaltsas, G., Burrin, J.M. and Grossman, A.B. (2001)
Pituitary 4, 49^55.
[11] Hassink, S.G., De Lancey, E., Sheslow, D.V., Smith-Kirwin,
S.M., O’Connor, D.M., Considine, R.V., Opentanova, I., Dostal,
K., Spear, M.L., Leef, K., Ash, M., Spitzer, A.R. and Funanage,
V.L. (1997) Pediatrics 100, E11^E16.
[12] Tartaglia, L.A., Dembski, M., Weng, X., Deng, N., Culpepper,
J., Devos, R., Richards, G.J., Camp¢eld, L.A., Clark, F.T.,
Deeds, J., Muir, C., Sanker, S., Moriarty, A., Moore, K.J., Smut-
ko, J.S., Mays, G.G., Woolf, E.A., Monroe, C.A. and Tepper,
R.I. (1995) Cell 83, 1263^1271.
[13] Bennett, B.D., Solar, G.P., Yuan, J.Q., Mathias, J., Thomas,
G.R. and Matthews, W. (1996) Curr. Biol. 6, 1170^1180.
[14] Vaisse, C., Halaas, J.L., Horvath, C.M., Darnell Jr., J.E., Sto¡el,
M. and Friedman, J.M. (1996) Nat. Genet. 14, 95^97.
[15] Bjorbak, C., Lavery, H.J., Bates, S.H., Olson, R.K., Davis, S.M.,
Flier, J.S. and Myers Jr., M.G. (2000) J. Biol. Chem. 275, 40649^
40657.
[16] Banks, A.S., Davis, S.M., Bates, S.H. and Myers Jr., M.G.
(2000) J. Biol. Chem. 275, 14563^14572.
[17] Ducy, P., Amling, M., Takeda, S., Priemel, M., Schilling, A.F.,
Beil, F.T., Shen, J., Vinson, C., Rueger, J.M. and Karsenty, G.
(2000) Cell 100, 197^207.
[18] Sisask, G., Bjurholm, A., Ahmed, M. and Kreicbergs, A. (1996)
J. Auton. Nerv. Syst. 59, 27^33.
[19] Widdowson, P.S. and Wilding, J.P. (2000) Front Horm. Res. 26,
71^86.
[20] Baldock, P.A., Sainsbury, A., Couzens, M., Enriquez, R.F., Tho-
FEBS 26404 11-9-02
J.E. Reseland, J.O. Gordeladze/FEBS Letters 528 (2002) 40^42 41
mas, G.P., Gardiner, E.M. and Herzog, H. (2002) J. Clin. Invest.
109, 915^921.
[21] Amling, M., Takeda, S. and Karsenty, G. (2000) Bioessays 22,
970^975.
[22] Ducy, P., Schinke, T. and Karsenty, G. (2000) Science 289, 1501^
1504.
[23] Karsenty, G. (2000) Trends Endocrinol. Metab. 11, 437^439.
[24] Karsenty, G. (2001) Recent Prog. Horm. Res. 56, 401^415.
[25] Takeda, S. and Karsenty, G. (2001) J. Bone Miner. Metab. 19,
195^198.
[26] Burguera, B., Hofbauer, L.C., Thomas, T., Gori, F., Evans,
G.L., Khosla, S., Riggs, B.L. and Turner, R.T. (2001) Endocri-
nology 142, 3546^3553.
[27] Peck, W.A., Rifas, L., Cheng, S.L. and Shen, V. (1986) Adv.
Exp. Med. Biol. 208, 255^259.
[28] Lian, L.B., Stein, C.M., Cabalis, E., Gehron Robey, P. and Bos-
key, A.l. (2002) in: Primer on the Metabolic Bone Diseases and
Disorders of Mineral Metabolism (Favus, M.J., Ed.), pp. 14^29,
Williams and Wilkins, Lippincott.
[29] Thomas, T., Gori, F., Khosla, S., Jensen, M.D., Burguera, B.
and Riggs, B.L. (1999) Endocrinology 140, 1630^1638.
[30] Steppan, C.M., Crawford, D.T., Chidsey-Frink, K.L., Ke, H.
and Swick, A.G. (2000) Regul. Pept. 92, 73^78.
[31] Gordeladze, J.O., Drevon, C.A., Syversen, U. and Reseland, J.E.
(2002) J. Cell Biochem. 85, 825^836.
[32] Holloway, W.R., Collier, F.M., Aitken, C.J., Myers, D.E.,
Hodge, J.M., Malakellis, M., Gough, T.J., Collier, G.R. and
Nicholson, G.C. (2002) J. Bone Miner. Res. 17, 200^209.
[33] Maor, G., Rochwerger, M., Segev, Y. and Phillip, M. (2002)
J. Bone Miner. Res. 17, 1034^1043.
FEBS 26404 11-9-02
J.E. Reseland, J.O. Gordeladze/FEBS Letters 528 (2002) 40^4242
